– Dr. Jeremy Levin steps down as President and CEO –
– Eyal Desheh, Teva’s Group EVP & Chief Financial Officer, named interim President and CEO –
JERUSALEM, Israel I October 30, 2013 I Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that its Board of Directors has agreed with Dr. Jeremy Levin that he will step down as President and Chief Executive Officer. The Board has named Eyal Desheh, Teva’s Executive Vice President and Chief Financial Officer, to fill the role of President and Chief Executive Officer on an interim basis, effective immediately, and it has formed a committee that will promptly begin to search for a permanent successor.
Dr. Phillip Frost, Chairman of the Board, stated “On behalf of the entire Board of Directors, I would like to thank Dr. Jeremy Levin for his meaningful contribution to Teva during the last two years. The Board and management team are fully committed to the implementation of Teva’s strategy, including the development of new compounds, making strategic acquisitions, forming joint ventures and the planned acceleration of the Company’s cost reduction program.”
“Since I joined Teva, we have made tremendous progress in setting a new course for the Company,” said Dr. Jeremy Levin. “I wish the Company and its people, who I respect greatly, every success. I look forward to pursuing new opportunities where I can continue to apply my experience and contribute to the evolution of the global pharmaceutical industry.”
“I have full confidence in the ability of Teva’s management and employees to achieve our goals and execute the strategy laid out for the Company,” said Eyal Desheh, who has served at Teva for over 12 years, including the last five as Chief Financial Officer. “My colleagues in Teva’s management and I will continue to drive execution and results in full collaboration with our Board of Directors, for the benefit of our patients, shareholders, customers and employees.”
As previously scheduled, Teva will report its third quarter 2013 financial results on October 31, 2013.
Conference Call
Teva will host a conference call on Wednesday, October 30, 2013, at 8:00 a.m. ET. The call will be webcast and can be accessed through the Company’s website at www.tevapharm.com, or by dialing in to 1.888.895.5271 (U.S. and Canada) or 1.847.619.6547 (International). The conference ID is 36015026. Following the conclusion of the call, a replay of the webcast will be available within 24 hours at the Company’s website at www.tevapharm.com. A replay of the call will also be available until November 6, 2013, at 11:59 p.m. ET, by calling 1.888.843.7419 (U.S. and Canada) or 1.630.652.3042 (International). The Conference ID is 36015026.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world’s leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in about 60 countries. Teva’s branded businesses focus on CNS, oncology, pain, respiratory and women’s health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $20.3 billion in net revenues in 2012.
SOURCE: Teva Pharmaceutical Industries
Post Views: 162
– Dr. Jeremy Levin steps down as President and CEO –
– Eyal Desheh, Teva’s Group EVP & Chief Financial Officer, named interim President and CEO –
JERUSALEM, Israel I October 30, 2013 I Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that its Board of Directors has agreed with Dr. Jeremy Levin that he will step down as President and Chief Executive Officer. The Board has named Eyal Desheh, Teva’s Executive Vice President and Chief Financial Officer, to fill the role of President and Chief Executive Officer on an interim basis, effective immediately, and it has formed a committee that will promptly begin to search for a permanent successor.
Dr. Phillip Frost, Chairman of the Board, stated “On behalf of the entire Board of Directors, I would like to thank Dr. Jeremy Levin for his meaningful contribution to Teva during the last two years. The Board and management team are fully committed to the implementation of Teva’s strategy, including the development of new compounds, making strategic acquisitions, forming joint ventures and the planned acceleration of the Company’s cost reduction program.”
“Since I joined Teva, we have made tremendous progress in setting a new course for the Company,” said Dr. Jeremy Levin. “I wish the Company and its people, who I respect greatly, every success. I look forward to pursuing new opportunities where I can continue to apply my experience and contribute to the evolution of the global pharmaceutical industry.”
“I have full confidence in the ability of Teva’s management and employees to achieve our goals and execute the strategy laid out for the Company,” said Eyal Desheh, who has served at Teva for over 12 years, including the last five as Chief Financial Officer. “My colleagues in Teva’s management and I will continue to drive execution and results in full collaboration with our Board of Directors, for the benefit of our patients, shareholders, customers and employees.”
As previously scheduled, Teva will report its third quarter 2013 financial results on October 31, 2013.
Conference Call
Teva will host a conference call on Wednesday, October 30, 2013, at 8:00 a.m. ET. The call will be webcast and can be accessed through the Company’s website at www.tevapharm.com, or by dialing in to 1.888.895.5271 (U.S. and Canada) or 1.847.619.6547 (International). The conference ID is 36015026. Following the conclusion of the call, a replay of the webcast will be available within 24 hours at the Company’s website at www.tevapharm.com. A replay of the call will also be available until November 6, 2013, at 11:59 p.m. ET, by calling 1.888.843.7419 (U.S. and Canada) or 1.630.652.3042 (International). The Conference ID is 36015026.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world’s leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in about 60 countries. Teva’s branded businesses focus on CNS, oncology, pain, respiratory and women’s health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $20.3 billion in net revenues in 2012.
SOURCE: Teva Pharmaceutical Industries
Post Views: 162